DOCSLIB.ORG

Rosai–Dorfman Disease: Tumor Biology, Clinical Features

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Rosai–Dorfman Disease: Tumor Biology, Clinical Features A high degree of clinical suspicion is needed to diagnose Rosai–Dorman disease. Eight-Spotted Skimmer. Photograph courtesy of Sherri Damlo. www.damloedits.com. Rosai–Dorfman Disease: Tumor Biology, Clinical Features, Pathology, and Treatment Samir Dalia, MD, Elizabeth Sagatys, MD, Lubomir Sokol, MD, PhD, and Timothy Kubal, MD Background: Rosai–Dorfman disease (RDD) is a rare, nonmalignant clinical entity characterized by a group of clinical symptoms and characteristic pathological features. Methods: Articles that reviewed tumor biology, clinical features, pathology, and treatment for RDD were identified in a search of the literature for the years 1990 to 2014. The results from this body of literature were reviewed and summarized. Results: Patients with RDD generally present with massive, painless cervical lymphadenopathy, fevers, and elevated inflammatory markers. Extranodal disease is typical, with the most common sites being the skin and the central nervous system. Rarely, the gastrointestinal tract is involved. Immunohistochemistry remains the mainstay of diagnosis with S100 and CD68 positive cells while CD1a will be negative of involved histiocytes. Histologically, the disease shows the classical characteristic finding of emperipolesis. Many patients do not require treatment; however, surgical resection remains the mainstay of treatment for symptomatic disease. The role of steroids, chemotherapy, and radiation therapy continue to be based on small case series and case reports. Conclusions: RDD has a variable clinical presentation; therefore, a high degree of suspicion and a thorough pathological review are necessary to diagnose this rare clinical entity. Although some patients will experience spontaneous resolution, others may require surgical resection or steroid therapy and radiation or chemother- apy. Given the rarity of the disease and the lack of a clear therapeutic pathway, referring patients to a tertiary center is recommended for confirming the diagnosis and treatment considerations. Introduction Rosai–Dorman disease (RDD), also known as sinus From the Departments of Medical Oncology (SD), Hematopathology histiocytosis with massive lymphadenopathy, was and Laboratory Medicine (ES), and Malignant Hematology (LS, originally described by Destombes in 1965.1 Subse- TK) at the H. Lee Moffitt Cancer Center & Research Institute and quently, it was characterized as a distinct clinicopatho- the University of South Florida Morsani College of Medicine (SD), 2 Tampa, Florida. logical disorder in 1969 by Rosai and Dorfman. In this Dr Dalia is now affiliated with Mercy Clinic Oncology-Hematology, nonmalignant disorder, patients typically present with Jopin, Missouri. fever, leukocytosis, and nonpainful cervical lymph- Submitted July 5, 2014; accepted August 12, 2014. adenopathy. Although the disease has a predilection Address correspondence to Samir Dalia, MD, Mercy Clinic Oncol- for the lymph nodes in the head and neck, RDD can ogy-Hematology, 3001 McClelland Boulevard, Joplin, MO 64804. also present in any extranodal site, with common sites E-mail: [email protected] including the skin and soft tissue, the central nervous No significant relationships exist between the authors and the com- panies/organizations whose products or services may be referenced system (CNS), and, less commonly, the gastrointestinal in this article. tract.3-9 Histology and immunohistochemistry help 322 Cancer Control October 2014, Vol. 21, No. 4 differentiate RDD from malignant disorders such as often affected than Caucasians and a male predomi- lymphoma and Langerhans cell histiocytosis. Although nance is present.11 Classically, most patients present adenopathy can be significant and disfiguring, RDD is in otherwise good health with symptoms of fever and usually self-limiting and eventually recedes, making massive, nonpainful cervical lymphadenopathy mim- systemic therapy rarely required.10 The aim of this icking lymphoma.2 Patients may have night sweats and review is to provide health care professionals with the weight loss. Painless maculopapular eruptions also scientific framework to gain a better understanding can be reported, and, unlike patients with Langerhans of the tumor biology, clinical features, pathology, and cell histiocytosis, osteolytic bone lesions are rare but treatment for RDD. sclerotic bone lesions sometimes occur.4,11,22,23 The workup of patients with suspected RDD is Tumor Biology similar to that of lymphoma. A detailed history and RDD is a disease of nonmalignant histiocytes that in- physical examination should be performed to exclude filtrate lymph nodes or extranodal tissues. RDD cells other causes of the adenopathy. It is worth noting that exhibit emperipolesis, the nondestructive phagocy- hepatosplenomegaly is rare in RDD, while it is com- tosis of lymphocytes or erythrocytes, which is the monly seen in other histiocytic disorders.11,24 Staging hallmark of the disease and required for diagnosis.2,8 should include contrast computed tomography (CT) The etiology of RDD is unknown and is considered an scans of the neck, chest, abdomen, and pelvis to look idiopathic histiocytosis. The search for an infectious for distant disease. The role of bone marrow biopsy agent linked to RDD has led to conflicting results. is unclear but is usually obtained because primary Some evidence suggests that immune dysfunction and bone marrow disorders are included in the differential viral infections, such as human herpesvirus (HHV), diagnosis of RDD. Laboratory workup should include parvovirus B19, and Epstein–Barr virus (EBV) may screening for EBV, cytomegalovirus, HHV-6, HHV-8, play a role in the pathogenesis.9,11-13 In particular, the and HIV. In addition, the laboratory workup should expression of the HHV-6 antigen has been identified include rheumatoid factor, an antinuclear antibody in the histiocytes present in RDD, while EBV and test, complete blood counts, liver and kidney func- parvovirus have been shown to be present in lympho- tion tests, immunoglobulin levels, and an erythrocyte cytes, which may eventually be phagocytosed by his- sedimentation rate (ESR). A total of 90% of patients tiocytes.13,14 However, in situ hybridization studies for has been reported to have an elevated ESR and poly- EBV-encoded RNA have shown the RDD histiocytes clonal hypergammaglobulinemia with a reversal of to be negative.11,15 In addition, 3 cases of RDD were the albumin:globulin ratio.24 Leukocytosis with neu- demonstrated to be negative for HHV-6.16 Therefore, trophilia, a normochromic normocytic anemia, and the definitive identity of an infectious agent behind a positive rheumatoid factor or antinuclear antibody RDD remains undetermined. value have all been reported.11,13,24 Hemolytic anemia Although RDD has been reported in patients with and eosinophilia are rare.11,24 Ideally, excisional biopsy immunoglobulin (Ig) G4-related disease, no clear ev- should be performed to obtain adequate tissue for idence suggests that these disorders have a common morphological and immunohistochemical analyses etiopathogenesis. In a recent analysis of 29 patients to make a diagnosis. with RDD, low numbers of IgG4-positive plasma cells The differential diagnosis of RDD is broad and and low IgG4/IgG ratios were present when compared is similar to other causes of lymphadenopathy. Non- with IgG4-related disease samples. Forkhead box malignant etiologies include tuberculosis, Wegener P3–positive T-regulatory cells were also lower in granulomatosis, sarcoidosis, IgG4-related disease, ju- number in patients with RDD when compared with venile xanthogranuloma, Erdheim–Chester disease, IgG4-related disease, suggesting that RDD does not fit Gaucher disease, and other histiocytic disorders such into the spectrum of IgG4-related disease.9,17,18 Germ- as Langerhans cell histiocytosis. Malignant etiologies line mutations in SLC29A3, which encodes an intracel- in the differential diagnosis of RDD include Hodgkin lular human equilibrative nucleoside transporter, have lymphoma, non-Hodgkin lymphoma, melanoma, leu- been reported in patients with familial RDD, suggest- kemia, and Langerhans cell sarcoma. ing that RDD may belong to a spectrum of disorders Extranodal involvement by RDD was initially with SLC29A3 mutations, including Faisalabad histio- thought to be uncommon, but some reports suggest cytosis, H syndrome, and pigmented hypertrichosis in that it may be present in up to 40% of cases.4,18 The the setting of insulin-dependent diabetes.19-21 most commonly involved extranodal sites include the skin, CNS, orbit and eyelid, upper respiratory tract, Clinical Features and the gastrointestinal tract.7-9,11-13,17,18,22,25-32 Typically, RDD manifests in childhood and early adult- CNS involvement in the setting of RDD is uncom- hood, with the majority of cases reported in the second mon and has been reported in 210 cases in the English and third decades of life.11 African Americans are more literature.8 The mean age of patients is 39 years and a October 2014, Vol. 21, No. 4 Cancer Control 323 male prevalence has been reported.8 Commonly, RDD RDD; lymph node structures, including sinusoids, presents with dura-based, extra-axial involvement of are absent (Fig 1).2,11 With fewer histiocytes present the cranium; by contrast, spinal cord and intracerebral showing emperipolesis in extranodal tissue, a careful involvement are rare.3,8 Constitutional symptoms are examination of the biopsies is required and immu- usually absent and neurological symptoms depend on nohistochemical stains may be
Load more

Recommended publications
  • FT117 Langerhans Cell Histiocytosis with Histopathological Features
    FT117 Langerhans cell histiocytosis with histopathological features, single center experience Histopatolojik özellikleriyle langerhans hücreli histiyositoz, tek merkez deneyimi Fahriye KILINÇ Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi, Tıbbi Patoloji Anabilim Dalı, Konya Aim: Langerhans cell histiocytosis (LCH) is a rare histiocytic disease, occurring in 2-10 children per million and 1-2 adults per million, and may have a wide variety of clinical manifestations. Infiltration can develop in almost any organ (the most commonly reported organs are bone, skin, lymph nodes, lungs, thymus, liver, spleen, bone marrow and central nervous system). We aimed to evaluate the histopathological features of the lesions and review the literature in pediatric patients referred to our department for pathological examination and diagnosed as LCH. Materials and Methods: Retrospectively, childhood cases diagnosed with LCH in 2012-2019 were screened by hospital automation system. Age, gender, lesion localizations of the cases were recorded and histopathological features were reviewed. Results: 5 male and 5 female total of 10 cases were detected. The youngest 3 were under the age of 1, the oldest was 16 years old. Localization; 6 of the cases were bone (2 femur, 3 skull bone, 1 scapula), 2 skin, 1 bone and lymph node, 1 lung and lymph node. Histopathology revealed histiocytic cells with grooved nuclei, eosinophilic cytoplasm with eosinophils, and neutrophils in some cases. Immunohistochemical CD1a staining was positive in all cases and positivities were present with S100 in applied 9 cases, CD68 in 4. Ki67 proliferation index was studied in 2 patients with bone localization, 15% and 20%. Conclusion: The term LCH is due to the morphological and immunophenotypic similarity of the infiltrating cells of this disease to Langerhans cells specialized as dendritic cells in the skin and mucous membranes.
    [Show full text]
  • Skin Biopsy Diagnosis of Langerhans Cell Neoplasms
    Chapter 3 Skin Biopsy Diagnosis of Langerhans Cell Neoplasms Olga L. Bohn, Julie Teruya-Feldstein and Sergio Sanchez-Sosa Additional information is available at the end of the chapter http://dx.doi.org/10.5772/55893 1. Introduction This chapter reviews the clinical presentation, histopathology, immunoprofile and molecular features of Langerhans cell neoplasms of the skin including Langerhans cell histiocytosis (LCH) and its malignant counterpart, Langerhans cell sarcoma (LCS). Biopsy of the skin is a useful method to confirm LCH/LCS diagnosis, as cutaneous involvement is seen in more than 50% cases. Skin can be the only presenting site of LCH, but it is usually seen as an integral part of multisystemic disease involvement. Langerhans cells (LC) are bone marrow-derived antigen presenting cells [1]. Although LC, dendritic cells and monocytic/histiocytic cells share a common multipotential progenitor cells that reside in the bone marrow, to the date, myeloid derived macrophages and dendritic cells constitute divergent lines of differentiation from bone marrow precursors [2]. However, recent evidence demonstrates that LC can be generated from lymphoid-committed CD4low precur‐ sors, suggesting the role of lineage plasticity/ trans-differentiation and clonal infidelity [3-4]. LC can be found in the epidermis and mucosal lining of multiple organs including cervix, vagina, stomach and esophagus. The specific immunophenotypic profile is helpful distin‐ guishing LCs, as they can express CD1a and langerin (CD207); in addition the detection of Birbeck granules, seen in both pathological and resting LC is a prominent feature [5]. LCH encompasses a spectrum of disease characterized by an uncontrolled proliferation of LC [5].
    [Show full text]
  • Histiocytic and Dendritic Cell Lesions
    1/18/2019 Histiocytic and Dendritic Cell Lesions L. Jeffrey Medeiros, MD MD Anderson Cancer Center Outline 2016 classification of Histiocyte Society Langerhans cell histiocytosis / sarcoma Erdheim-Chester disease Juvenile xanthogranuloma Malignant histiocytosis Histiocytic sarcoma Interdigitating dendritic cell sarcoma Follicular dendritic cell sarcoma Rosai-Dorfman disease Hemophagocytic lymphohistiocytosis Writing Group of the Histiocyte Society 1 1/18/2019 Major Groups of Histiocytic Lesions Group Name L Langerhans-related C Cutaneous and mucocutaneous M Malignant histiocytosis R Rosai-Dorfman disease H Hemophagocytic lymphohistiocytosis Blood 127: 2672, 2016 L Group Langerhans cell histiocytosis Indeterminate cell tumor Erdheim-Chester disease S100 Normal Langerhans cells Langerhans Cell Histiocytosis “Old” Terminology Eosinophilic granuloma Single lesion of bone, LN, or skin Hand-Schuller-Christian disease Lytic lesions of skull, exopthalmos, and diabetes insipidus Sidney Farber Letterer-Siwe disease 1903-1973 Widespread visceral disease involving liver, spleen, bone marrow, and other sites Histiocytosis X Umbrella term proposed by Sidney Farber and then Lichtenstein in 1953 Louis Lichtenstein 1906-1977 2 1/18/2019 Langerhans Cell Histiocytosis Incidence and Disease Distribution Incidence Children: 5-9 x 106 Adults: 1 x 106 Sites of Disease Poor Prognosis Bones 80% Skin 30% Liver Pituitary gland 25% Spleen Liver 15% Bone marrow Spleen 15% Bone Marrow 15% High-risk organs Lymph nodes 10% CNS <5% Blood 127: 2672, 2016 N Engl J Med
    [Show full text]
  • Cutaneous Neonatal Langerhans Cell Histiocytosis
    F1000Research 2019, 8:13 Last updated: 18 SEP 2019 SYSTEMATIC REVIEW Cutaneous neonatal Langerhans cell histiocytosis: a systematic review of case reports [version 1; peer review: 1 approved with reservations, 1 not approved] Victoria Venning 1, Evelyn Yhao2,3, Elizabeth Huynh2,3, John W. Frew 2,4 1Prince of Wales Hospital, Randwick, Sydney, NSW, 2033, Australia 2University of New South Wales, Sydney, NSW, 2033, Australia 3Sydney Children's Hospital, Randwick, NSW, 2033, Australia 4Department of Dermatology, Liverpool Hospital, Sydney, Sydney, NSW, 2170, Australia First published: 03 Jan 2019, 8:13 ( Open Peer Review v1 https://doi.org/10.12688/f1000research.17664.1) Latest published: 03 Jan 2019, 8:13 ( https://doi.org/10.12688/f1000research.17664.1) Reviewer Status Abstract Invited Reviewers Background: Cutaneous langerhans cell histiocytosis (LCH) is a rare 1 2 disorder characterized by proliferation of cells with phenotypical characteristics of Langerhans cells. Although some cases spontaneously version 1 resolve, no consistent variables have been identified that predict which published report report cases will manifest with systemic disease later in childhood. 03 Jan 2019 Methods: A systematic review (Pubmed, Embase, Cochrane database and all published abstracts from 1946-2018) was undertaken to collate all reported cases of cutaneous LCH in the international literature. This study 1 Jolie Krooks , Florida Atlantic University, was registered with PROSPERO (CRD42016051952). Descriptive statistics Boca Raton, USA and correlation analyses were undertaken. Bias was analyzed according to Milen Minkov , Teaching Hospital of the GRADE criteria. Medical University of Vienna, Vienna, Austria Results: A total of 83 articles encompassing 128 cases of cutaneous LCH were identified.
    [Show full text]
  • Beyond Langerhans Cell Histiocytosis Related to Smoking
    Radiología. 2019;61(3):215---224 www.elsevier.es/rx RADIOLOGY THROUGH IMAGES Pulmonary histiocytosis: Beyond Langerhans cell ଝ histiocytosis related to smoking a b a c d b,e,∗ C. Trejo Gallego , J. Bueno , E. Cruces , E.B. Stelow , N. Mancheno˜ , L. Flors a Servicio de Radiología, Hospital Universitario Morales Meseguer, Universidad de Murcia, Murcia, Spain b Department of Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, VA, United States c Department of Pathology, University of Virginia Health System, Charlottesville, VA, United States d Servicio de Anatomía Patológica, Hospital Universitario y Politécnico la Fe, Valencia, Spain e Department of Radiology, One Hospital Dr, University of Missouri Health System, Columbia, MO, United States Received 21 October 2017; accepted 16 November 2018 Available online 24 January 2019 KEYWORDS Abstract Langerhans cells Objective: To review the imaging findings for the different types of pulmonary histiocy- histiocytosis; tosis. In particular, in addition to the well-known pulmonary Langerhans cell histiocytosis Erdheim---Chester related to smoking and its possible appearance in nonsmokers, we focus on non-Langerhans disease; cell histiocytosis in Rosai---Dorfman disease and Erdheim---Chester disease. We also review the Sinus histiocytosis; etiopathogenesis, histology, clinical presentation, and treatment of pulmonary histiocytosis. Computed Conclusion: Langerhans cell histiocytosis, Rosai---Dorfman disease, and Erdheim---Chester dis- tomography ease are idiopathic
    [Show full text]
  • Histiocytic Sarcoma in a 3-Year-Old Male: a Case Report
    Histiocytic Sarcoma in a 3-Year-Old Male: A Case Report Samuel Buonocore, MD*; Alfredo L. Valente, MD‡; Daniel Nightingale, MD‡; Jeffrey Bogart, MD§; and Abdul-Kader Souid, MD, PhD* ABSTRACT. We describe a pediatric patient with his- CASE REPORT tiocytic sarcoma involving the T6 and L4 vertebral bodies This previously healthy 3-year-old boy experienced intermit- and the lungs. His tumor progressed during chemother- tent low back pain radiating to the right inguinal region for ϳ2 apy designed for Langerhans’ cell histiocytosis and sar- months. His symptoms initially responded to ibuprofen. The pain coma. High-dose radiation, on the other hand, was intensity increased over a 2-week period, and he refused to walk. effective. Pediatrics 2005;116:e322–e325. URL: www. Review of systems was significant for pain with urination. With the exception of being unable to stand, his physical examination pediatrics.org/cgi/doi/10.1542/peds.2005-0026; sarcoma, was unremarkable. The laboratory tests showed normal blood histiocytes, Langerhans’ cell histiocytosis, histiocytic sar- counts and normal liver and renal function. An MRI showed coma. collapse of the T6 and L4 vertebral bodies and a soft tissue mass in the anterior epidural space at the level of L4 (Fig 1 A and B). The chest and abdominal computed tomography (CT) scans were nor- ABBREVIATIONS. LCH, Langerhans’ cell histiocytosis; CT, com- mal. Bone marrow aspiration revealed no malignant infiltration. A puted tomography; 2CdA, 2-chlorodeoxyadenosine. technetium bone scan showed increased uptake limited to the T6 and L4 regions. CT-scan–guided needle biopsy of the L4 mass revealed infiltrative proliferation of the bone and soft tissue by istiocytic and dendritic neoplasms are rare, sheets and clusters of large ovoid cells with abundant eosinophilic cytoplasm (Fig 2A).
    [Show full text]
  • Langerhans Cell Sarcoma with an Aberrant Cytoplasmic CD3 Expression Zhaodong Xu1*, Ruth Padmore1, Carolyn Faught2, Lisa Duffet2 and Bruce F Burns3
    Xu et al. Diagnostic Pathology 2012, 7:128 http://www.diagnosticpathology.org/content/7/1/128 CASE REPORT Open Access Langerhans cell sarcoma with an aberrant cytoplasmic CD3 expression Zhaodong Xu1*, Ruth Padmore1, Carolyn Faught2, Lisa Duffet2 and Bruce F Burns3 Abstract: Langerhans cell sarcoma is a rare and aggressive high grade hematopoietic neoplasm with a dismal prognosis. It has a unique morphological and immunotypic profile with a CD1a/ langerin/S100 + phenotype. T cell lineage markers except for CD4 in Langerhans cell sarcoma have not been documented previously. We report a case of 86 year-old male of Caucasian descent who presented with an enlarging right neck mass over 2 months with an underlying unknown cause of anemia. Computed tomography scan of the neck, chest and abdomen revealed generalized lymphadenopathy and mild splenomegaly suspicious for lymphoma. Diagnostic core biopsy performed on right neck mass revealed a possible T cell lymphoma with expression of T cell lineage specific marker CD3 but conclusive diagnosis could not be made due to insufficient core biopsy sample. Further excisional biopsy performed on a left inguinal node showed a hematopoietic neoplasm with features of Langerhans cell sarcoma with a focal cytoplasmic CD3 expression in 30-40% of the tumor cells. PCR for T cell receptor (TCR) gene rearrangement failed to demonstrate a clonal gene rearrangement in the tumor cells arguing against a T cell lineage transdifferentiation, suggesting an aberrant CD3 expression. To the best of our knowledge, this case represents the first report of Langerhans cell sarcoma with an aberrant cytoplasmic CD3 expression. Virtual slides: http://www.diagnosticpathology.diagnomx.eu/vs/2065486371761991 Keywords: Langerhans cell sarcoma (LCS), Langerhans cell histiocytosis (LCH), CD3, Aberrant expression, Lineage plasticity, Transdifferentiation Background langerin/S100+ [2,3] but without B- and T-cell lineage According to the most recent WHO Classification of markers except for CD4 [4].
    [Show full text]
  • Histiocytic Sarcoma Originating in the Lung in a 16-Year-Old Male
    J Clin Exp Hematop Vol. 55, No. 1, June 2015 Case Study Histiocytic Sarcoma Originating in the Lung in a 16-Year-Old Male Sakura Tomita,1) Go Ogura,1) Chie Inomoto,1) Hiroshi Kajiwara,1) Ryota Masuda,2) Masayuki Iwazaki,2) Masaru Kojima,3) and Naoya Nakamura1) We report a 16-year-old male with histiocytic sarcoma (HS) originating in the lung. Partial resection of the lung was performed for a 3-cm mass with a clear boundary detected in the right inferior pulmonary lobe on a health checkup. Histologically, the tumor infiltrated into the surrounding tissue, and was comprised of spindle cells, mainly, and foam cells accompanied by mild nuclear atypia. The tumor cells were immunohistochemically positive for CD68 and CD163, indicating histiocytic lineage and the MIB-1-positive rate was low. Spindle cell morphology of HS is quite rare and only 3 cases of pulmonary HS have previously been reported. 〔J Clin Exp Hematop 55(1) : 45-49, 2015〕 Keywords: histiocytic sarcoma, lung, spindle cells, foamy cells spindle cells, mainly, and foam cells. INTRODUCTION Histiocytic sarcoma (HS) is a malignant hematopoietic CASE REPORT tumor consisting of cells similar to mature histiocytes.1-4 It is extremely rare and the age of onset widely ranges from 6 The patient was a 16-year-old male who exhibited an months to 89 years, with no gender difference; the incidence abnormal shadow detected on a health checkup. He had no is high in adults, showing a large peak at 50-69 years, but also particular past or familial medical history.
    [Show full text]
  • Langerhans Cell Histiocytosis
    2020 Virtual Pathology Course 08/22/2020 Saja Asakrah, MD PhD Assistant professor Hematopathologist Saja Asakrah, MD Ph.D Disclosure • No conflict of interest to disclose Case #13 A 44 year old male with no past medical history presented with a painless slowly growing lump in front of his left ear that he noticed one year prior. Histiocytes Cell of origin and classification Reactive versus clonal/neoplastic histiocytic infiltrate Malignant histiocytic infiltrate (sarcoma) Associated with hematopoietic or non hematopoietic lesions Classic morphology of Langerhans cell histioyocytosis involving a lymph node CD1a Langerin S100 HLA-DR A case of Erdheim-Chester disease involving tibia Histiocytes Cell of origin and classification Reactive versus clonal/neoplastic histiocytic infiltrate Malignant histiocytic infiltrate (sarcoma) Associated with hematopoietic or non hematopoietic lesions Dermatopathic lymphadenopathy In: Atlas of Lymph Node Pathology. Atlas of Anatomic Pathology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7959-8_31 Reactive histiocytosis in a left neck mass core biopsy CD1a Cytokeratin AE1/AE3 Dx Nasopharyngeal carcinoma EBV ISH In challenging cases mutational analysis may be helpful in supporting a clonal process REVIEW Volume 23 Number 4 July 2016 MAPK pathway mutations • B-Raf proto-oncogen: In contrast to recurrent BRAF V600E mutations, other mutations in BRAF have been found only rarely in histiocytoses. These include BRAF V600D and BRAF V600insDLAT in LCH, BRAF F595L in histiocytic sarcoma • A-Raf Proto-oncogen: Recurrent in non-LCH and are present in 21% of ECD. • RAS isoforms: This includes NRAS mutations in 3–7% of ECD and less frequently in LCH.
    [Show full text]
  • Multifocal Langerhans Cell Sarcoma Involving Epidermis: a Case Report and Review Changsong Wang1*, Yanping Chen1, Chunfang Gao1, Jian Yin1 and Hong Li2
    Wang et al. Diagnostic Pathology 2012, 7:99 http://www.diagnosticpathology.org/content/7/1/99 CASE REPORT Open Access Multifocal Langerhans cell sarcoma involving epidermis: a case report and review Changsong Wang1*, Yanping Chen1, Chunfang Gao1, Jian Yin1 and Hong Li2 Abstract Objective: To study the clinico-pathological characteristics of Langerhans cell sarcoma (LCS) which involving epidermis. Methods: A case of primary multifocal LCS was analyzed in histopathology and immunophenotype. Results: A 41-year-old man with multifocal cutaneous LCS involving the inguina and waist was reported. Clinical and pathology data were available. Neoplastic cells with markedly malignant cytological features were observed. Tumor cells exhibited irregular shape with abundant and eosinophilic red staining cytoplasm; large, irregular-shaped, showing lobulated or dented nucleus and some cells with a longitudinal nuclear groove and prominent nucleoli. The tumor cells expressed CD1a, Langerin (CD207), S-100 protein, CD68 and vimentin, and did not express pan-T or B cell markers and epithelial markers. The patient died less than 1 year after diagnosis due to local recurrence and metastasis to the lung, despite the administration of local radiation and chemotherapy. Conclusions: LCS is a tumor with markedly malignant cytological features that originates from Langerhans cells. Primary multifocal neoplasms involving epidermis is even rare. Accurate diagnosis is based on the histopathological and immunohistochemical of the tumor cells. Virtual slide: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/ 1182345104754765. Keywords: Langerhans cell sarcoma, Multiple focus, Langerin, CD1a Background LCH is difficult. LCS occure at any age and involve The Langerhans cell tumors were classified into Langer- many organs or tissues, such as bone, lung, lymph hans cell histiocytosis (LCH) and Langerhans cell sar- nodes, liver and soft tissues.
    [Show full text]
  • Extra Nodal Rosai Dorfman Disease of Nasal Septal Mucosa Without Lymphadenopathy
    Journal of Pathology of Nepal (2016) Vol. 6, 968 - 970 Journal of cal Patholo lini gis f C t o o f N n e io p t a a l i - c 2 PATHOLOGY o 0 s 1 s 0 A N u e d p n of Nepal a l a M m e h d t i a c K al , A ad ss o oc n R www.acpnepal.com iatio bitio n Building Exhi Case Report Extra nodal Rosai Dorfman disease of nasal septal mucosa without lymphadenopathy Raje P1, Vyas P1 1Department of Surgical Pathology and Cytology, Bombay Hospital Indore – Indore, India. ABSTRACT Keywords: Nasal septum; Rosai–Dorman disease, also known as sinus histiocytosis with massive lymphadenopathy, typically Rosai–Dorman disease; presents as massive enlargement of lymph nodes accompanied by systemic symptoms. Extranodal Lymphadenopathy involvement is also known usually in head and neck regions. Rarely the disease presents at extranodal sites only without involvement of lymph nodes. We present a case of 58 years-old female who presented with mass in nasal septum without involvement of lymph nodes. The mass was removed surgically and diagnosis was made on histological grounds with classical indings of histiocytic proliferation and emperipolesis. INTRODUCTION Rosai–Dorman disease (RDD), also known as sinus In 43% cases disease may have extra nodal involvement4, histiocytosis with massive lymphadenopathy (SHML), most common sites being nasal cavities, skin, eyes, orbit, a rare and usually self limiting disease, was originally eyelids, bones, soft tissue, the central nervous system, upper described by Destombes in 1965.1 Subsequently; in 1969, it respiratory tract
    [Show full text]
  • Dataset for the Histopathological Reporting of Lymphomas
    Standards for specialist laboratory integration and Dataset for the histopathological reporting of lymphomas October 2015 Authors: Dr Stefan Dojcinov, University Hospital of Wales Dr Bridget Wilkins, St Thomas’ Hospital Dr Maria Calaminici, Barts Health NHS Trust Unique document number G142 Document name Standards for specialist laboratory integration and Dataset for the histopathological reporting of lymphomas Version number 2 Produced by Dr Stefan Dojcinov, Consultant Histopathologist, All Wales Lymphoma Panel, Department of Cellular Pathology, University Hospital of Wales, Cardiff. Dr Bridget Wilkins, Consultant Haematopathologist, Cellular Pathology Department St Thomas’ Hospital, London. Dr Maria Calaminici, Consultant Haematopathologist, Department of Cellular Pathology, Barts Health NHS Trust, London. Date active 4 February 2015 Date for full review 4 March 2015 Comments This document replaces the 1st edition of Dataset for histopathological reporting of lymphomas, published in 2002. In accordance with the College’s pre-publications policy, this document was on The Royal College of Pathologists’ website for consultation from 4 February to 4 March 2015. Seventeen items of feedback were received. The authors considered them and amended the document as appropriate. Please email [email protected] if you wish to see the responses and comments. Dr Lorna Williamson Director of Publishing and Engagement The Royal College of Pathologists Fourth Floor, 21 Prescot Street, London, E1 8BB Tel: 020 7451 6700 Fax: 020 7451 6701 Web: www.rcpath.org Registered charity in England and Wales, no. 261035 © 2015, The Royal College of Pathologists This work is copyright. You may download, display, print and reproduce this document for your personal, non-commercial use. Apart from any use as permitted under the Copyright Act 1968 or as set out above, all other rights are reserved.
    [Show full text]